Brexanolone by Sage Therapeutics for Alcohol Dependence: Likelihood of Approval

Brexanolone is under clinical development by Sage Therapeutics and currently in Phase I for Alcohol Dependence.

Bispecifics continue impressive efficacy streak, but companies look to reduce side effects: #ASH23

SAN DIEGO — Bispecific antibodies from Regeneron, Johnson & Johnson, AbbVie and Roche continue to show impressive efficacy in lymphomas and myeloma based on new

December 13, 2023

TLDR – TDR News Highlights Last 24 Hours – January 26, 2024

This summary of TDR News Highlights from the last 24 hours (January 26, 2024) highlights key updates in the cannabis industry, including store openings, market

January 29, 2024

Home-Based Phototherapy for Psoriasis Matches Office Efficacy With Better QOL

SAN DIEGO — Home-based phototherapy for psoriasis achieved outcomes similar to office-based therapy, suggesting a potential for more convenient, less expensive treatment for some patients,

March 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.